Discounted Cash Flow (DCF) Analysis Unlevered

Provention Bio, Inc. (PRVB)

$4.08

+0.18 (+4.62%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 4.08 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 4.08
Beta 2.738
Diluted Shares Outstanding 63.10
Cost of Debt
Tax Rate 0.87
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 15.664
Total Debt 0.59
Total Equity 257.45
Total Capital 258.04
Debt Weighting 0.23
Equity Weighting 99.77
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.00%0.70%0.00%0.53%0.87%0.42%0.42%0.42%0.42%0.42%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure ----1.11-0.96-----
UFCF ----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -77.60
Equity Value -
Shares Outstanding 63.10
Equity Value Per Share -